Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis
DOI:
https://doi.org/10.2340/actadv.v104.40796Keywords:
atopic eczema, biologics, side effects, weight gainAbstract
This cohort study used prospectively collected data from the Swedish national quality registry, SwedAD, to investigate weight gain as a possible side effect of dupilumab treatment for atopic dermatitis. Patients on dupilumab were compared with patients on other systemic medications, e.g., methotrexate, cyclosporine, or Janus kinase inhibitors, and possible risk factors for weight change during treatment with dupilumab were analysed. All patients aged 18 years or above, included in SwedAD between March 2018 and April 2023, who initiated systemic treatment at or after inclusion and had data on weight at baseline and at least 1 follow-up weight measurement were included (n = 157). After 2 years on dupilumab, patients had a mean weight gain of 1.6 kg (p = 0.007, 95% confidence interval [CI] 0.4–2.7). In the multivariable analysis, controlling for age at start, sex, asthma, and body mass index at start, dupilumab was associated with higher weight gain than other systemic treatments (3.3 kg, p = 0.005 [95% CI 1.0–5.6]). Asthma was associated with weight loss; male sex tended to be associated with weight gain.
Downloads
References
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345-360.
https://doi.org/10.1016/S0140-6736(20)31286-1 DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.
https://doi.org/10.1111/jdv.16892 DOI: https://doi.org/10.1111/jdv.16892
Ivert LU, Svedbom A, Lundqvist M, Wahlgren CF, Bradley M, Johansson EK. The impact of systemic treatment of atopic dermatitis on depressive symptoms: a prospective clinical cohort study. Acta Derm Venereol 2022; 102: adv00801.
https://doi.org/10.2340/actadv.v102.803 DOI: https://doi.org/10.2340/actadv.v102.803
Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol 2020; 100: adv00161.
https://doi.org/10.2340/00015555-3511 DOI: https://doi.org/10.2340/00015555-3511
Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis. J Cutan Med Surg 2022; 26: 613-621.
https://doi.org/10.1177/12034754221130969 DOI: https://doi.org/10.1177/12034754221130969
Bieber T, Paller AS, Kabashima K, Feely M, Rueda MJ, Ross Terres JA, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereol 2022; 36: 1432-1449.
https://doi.org/10.1111/jdv.18225 DOI: https://doi.org/10.1111/jdv.18225
Nettis E, Masciopinto L, Di Leo E, De Candia N, Albanesi M, Di Bona D, et al. Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis. Clin Mol Allergy 2021; 19: 9.
https://doi.org/10.1186/s12948-021-00144-x DOI: https://doi.org/10.1186/s12948-021-00144-x
Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 2021; 148: 927-940.
https://doi.org/10.1016/j.jaci.2021.08.009 DOI: https://doi.org/10.1016/j.jaci.2021.08.009
Johansson EK, Ivert LU, Bradley B, Lundqvist M, Bradley M. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. BMC Dermatol 2020; 20: 8.
https://doi.org/10.1186/s12895-020-00103-0 DOI: https://doi.org/10.1186/s12895-020-00103-0
Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther 2011; 24: 446-451.
https://doi.org/10.1111/j.1529-8019.2011.01439.x DOI: https://doi.org/10.1111/j.1529-8019.2011.01439.x
Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle 2017; 8: 639-646.
https://doi.org/10.1002/jcsm.12189 DOI: https://doi.org/10.1002/jcsm.12189
Darkhal P, Gao M, Ma Y, Liu D. Blocking high-fat diet-induced obesity, insulin resistance and fatty liver by overexpression of Il-13 gene in mice. Int J Obes (Lond) 2015; 39: 1292-1299.
https://doi.org/10.1038/ijo.2015.52 DOI: https://doi.org/10.1038/ijo.2015.52
Sadik A, Somarribas Patterson LF, Öztürk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell 2020; 182: 1252-1270.e1234.
https://doi.org/10.1016/j.cell.2020.07.038 DOI: https://doi.org/10.1016/j.cell.2020.07.038
Agudelo LZ, Ferreira DMS, Cervenka I, Bryzgalova G, Dadvar S, Jannig PR, et al. Kynurenic acid and Gpr35 regulate adipose tissue energy homeostasis and inflammation. Cell Metab 2018; 27: 378-392.e375.
https://doi.org/10.1016/j.cmet.2018.01.004 DOI: https://doi.org/10.1016/j.cmet.2018.01.004
Alsterholm M, Svedbom A, Anderson CD, Holm Sommar L, Ivert LU, Josefson A, et al. Establishment and utility of SwedAD: a nationwide Swedish registry for patients with atopic dermatitis receiving systemic pharmacotherapy. Acta Derm Venereol 2023; 103: adv7312.
https://doi.org/10.2340/actadv.v103.7312 DOI: https://doi.org/10.2340/actadv.v103.7312
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353-1357.
https://doi.org/10.1111/bjd.13662 DOI: https://doi.org/10.1111/bjd.13662
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.
https://doi.org/10.1111/bjd.12590 DOI: https://doi.org/10.1111/bjd.12590
Svanborg P, Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand 1994; 89: 21-28.
https://doi.org/10.1111/j.1600-0447.1994.tb01480.x DOI: https://doi.org/10.1111/j.1600-0447.1994.tb01480.x
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Reich A, Riepe C, Anastasiadou Z, Mędrek K, Augustin M, Szepietowski JC, et al. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol 2016; 96: 978-980.
https://doi.org/10.2340/00015555-2433 DOI: https://doi.org/10.2340/00015555-2433
Midttun Ø, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009; 23: 1371-1379.
https://doi.org/10.1002/rcm.4013 DOI: https://doi.org/10.1002/rcm.4013
Ascott A, Mansfield KE, Schonmann Y, Mulick A, Abuabara K, Roberts A, et al. Atopic eczema and obesity: a population-based study. Br J Dermatol 2021; 184: 871-879.
https://doi.org/10.1111/bjd.19597 DOI: https://doi.org/10.1111/bjd.19597
Caman OK, Calling S, Midlöv P, Sundquist J, Sundquist K, Johansson SE. Longitudinal age-and cohort trends in body mass index in Sweden: a 24-year follow-up study. BMC Public Health 2013; 13: 893.
https://doi.org/10.1186/1471-2458-13-893 DOI: https://doi.org/10.1186/1471-2458-13-893
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486-2496.
https://doi.org/10.1056/NEJMoa1804092 DOI: https://doi.org/10.1056/NEJMoa1804092
Han J, Nguyen J, Kim Y, Geng B, Romanowski G, Alejandro L, et al. Effect of inhaled corticosteroid use on weight (BMI) in pediatric patients with moderate-severe asthma. J Asthma 2019; 56: 263-269.
https://doi.org/10.1080/02770903.2018.1455853 DOI: https://doi.org/10.1080/02770903.2018.1455853
Jenney ME, Childs C, Mabin D, Beswick MV, David TJ. Oxygen consumption during sleep in atopic dermatitis. Arch Dis Child 1995; 72: 144-146.
https://doi.org/10.1136/adc.72.2.144 DOI: https://doi.org/10.1136/adc.72.2.144
Rohner MH, Thormann K, Cazzaniga S, Yousefi S, Simon HU, Schlapbach C, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy 2021; 76: 1268-1270.
https://doi.org/10.1111/all.14664 DOI: https://doi.org/10.1111/all.14664
Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 2014; 157: 1279-1291.
https://doi.org/10.1016/j.cell.2014.03.065 DOI: https://doi.org/10.1016/j.cell.2014.03.065
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Mahsa Tayefi, Axel Svedbom, Lina Ivert, Maria Lundqvist, Jorge Ruas, Maria Bradley, Emma Johansson
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
